Insider · CIK 0001202094

MANHARD KIMBERLY

Reports to the SEC for 4 companies · LA JOLLA, CA

sec.gov

Transactions

Companies

Filings

CIK

0001202094

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-15	INBXInhibrx Biosciences, Inc.S Sale	Director	SSale	−500 sh	$105.05	−$52.5K	7,500
2026-09-14	INBXInhibrx Biosciences, Inc.S Sale	Director	SSale	−500 sh	$110.26	−$55.1K	8,000
2026-09-11	INBXInhibrx Biosciences, Inc.S Sale	Director	SSale	−500 sh	$111.78	−$55.9K	8,500
2026-09-09	INBXInhibrx Biosciences, Inc.S Sale	Director	SSale	−500 sh	$115.80	−$57.9K	9,000
2026-09-08	INBXInhibrx Biosciences, Inc.S Sale	Director	SSale	−500 sh	$115.14	−$57.6K	9,500
2026-06-03	INBXInhibrx Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2026-06-03	INBXInhibrx Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2025-05-28	INBXInhibrx Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2024-08-28	INBXInhibrx Biosciences, Inc.P Purchase	Director	PPurchase	+10K sh	$13.98	+$140K	10,000
2024-05-30	Inhibrx, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−3,500 sh	—	—	0
2024-05-30	Inhibrx, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2024-05-30	Inhibrx, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2024-05-30	Inhibrx, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2024-05-30	Inhibrx, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17.3K sh	—	—	0
2024-05-30	INBXInhibrx Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2023-05-25	Inhibrx, Inc.Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2023-04-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+1,250 sh	—	—	25,183
2023-04-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+4,564 sh	—	—	29,747
2023-04-13	HRTXHERON THERAPEUTICS, INC. /DE/F Tax Payment	EVP, Drug Development	FTax Payment	−1,417 sh	$2.88	−$4,080.96	28,330
2023-04-13	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	−1,250 sh	—	—	7,500
2023-04-13	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	−4,564 sh	—	—	27,936
2023-01-18	HRTXHERON THERAPEUTICS, INC. /DE/ · Performance Stock UnitsA Award	EVP, Drug Development	AAward	+149K sh	—	—	149,365
2023-01-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+1,250 sh	—	—	21,381
2023-01-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+4,564 sh	—	—	25,945
2023-01-13	HRTXHERON THERAPEUTICS, INC. /DE/F Tax Payment	EVP, Drug Development	FTax Payment	−2,012 sh	$3.17	−$6,378.04	23,933
2023-01-13	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	−1,250 sh	—	—	8,750
2023-01-13	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	−4,564 sh	—	—	32,500
2022-10-31	HRTXHERON THERAPEUTICS, INC. /DE/J Other	EVP, Drug Development	JOther	+1,655 sh	$3.27	+$5,415.988	20,131
2022-10-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+1,250 sh	—	—	15,924
2022-10-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+4,564 sh	—	—	20,488
2022-10-13	HRTXHERON THERAPEUTICS, INC. /DE/F Tax Payment	EVP, Drug Development	FTax Payment	−2,012 sh	$3.76	−$7,565.12	18,476
2022-10-13	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	−1,250 sh	—	—	10,000
2022-10-13	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	−4,564 sh	—	—	37,064
2022-07-25	HRTXHERON THERAPEUTICS, INC. /DE/ · Employee Stock Option (Right to Buy)A Award	EVP, Drug Development	AAward	+166K sh	—	—	165,961
2022-07-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+1,250 sh	—	—	12,122
2022-07-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+4,564 sh	—	—	16,686
2022-07-13	HRTXHERON THERAPEUTICS, INC. /DE/F Tax Payment	EVP, Drug Development	FTax Payment	−2,012 sh	$3.01	−$6,056.12	14,674
2022-07-13	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	−1,250 sh	—	—	11,250
2022-07-13	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	−4,564 sh	—	—	41,628
2022-05-25	Inhibrx, Inc.Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	50,759
2022-05-03	HRTXHERON THERAPEUTICS, INC. /DE/S Sale	EVP, Drug Development	SSale	−1,504 sh	$4.76	−$7,153.626	10,872
2022-04-29	HRTXHERON THERAPEUTICS, INC. /DE/J Other	EVP, Drug Development	JOther	+1,504 sh	$3.84	+$5,778.368	12,376
2022-04-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+1,250 sh	—	—	8,320
2022-04-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+4,564 sh	—	—	12,884
2022-04-13	HRTXHERON THERAPEUTICS, INC. /DE/F Tax Payment	EVP, Drug Development	FTax Payment	−2,012 sh	$6.07	−$12.2K	10,872
2022-04-13	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	−1,250 sh	—	—	12,500
2022-04-13	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	−4,564 sh	—	—	46,192
2022-01-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+1,250 sh	—	—	4,518
2022-01-13	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Drug Development	MExercise/Conversion	+4,564 sh	—	—	9,082
2022-01-13	HRTXHERON THERAPEUTICS, INC. /DE/F Tax Payment	EVP, Drug Development	FTax Payment	−2,012 sh	$8.30	−$16.7K	7,070

Recent filings

Accepted (ET)
Sep 184/A
MANHARD KIMBERLY0001202094-26-000009
SEC(opens sec.gov)
Sep 154
MANHARD KIMBERLY0001202094-26-000006
SEC(opens sec.gov)
Sep 104
MANHARD KIMBERLY0001202094-26-000004
SEC(opens sec.gov)
Jun 44
MANHARD KIMBERLY0001202094-26-000002
SEC(opens sec.gov)
May 294
MANHARD KIMBERLY0002007919-25-000072
SEC(opens sec.gov)
Aug 304
MANHARD KIMBERLY0002007919-24-000042
SEC(opens sec.gov)
May 304
MANHARD KIMBERLY0000950142-24-001494
SEC(opens sec.gov)
May 304
MANHARD KIMBERLY0000950142-24-001501
SEC(opens sec.gov)
May 304
MANHARD KIMBERLY0001739614-23-000052
SEC(opens sec.gov)
Apr 174
MANHARD KIMBERLY0001209191-23-024497
SEC(opens sec.gov)

Companies

Address

C/O INHIBRX BIOSCIENCES, INC. 11025 NORTH TORREY PINES ROAD, SUITE 140

LA JOLLA, CA, 92037